知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.022 seconds)

    Therapeutic agent for thrombocytopenia and indolocarbazole derivatives
    11.
    发明授权
    Therapeutic agent for thrombocytopenia and indolocarbazole derivatives 失效
    血小板减少症和吲哚并咔唑衍生物的治疗剂

    公开(公告)号：US5629304A

    公开(公告)日：1997-05-13

    申请号：US637590

    申请日：1996-04-25

    Applicant: Chikara Murakata ,  Fumihiko Kanai ,  Yutaka Saitoh ,  Yukimasa Shiotsu ,  Takako Shiraki ,  Tatsuya Tamaoki ,  Shiro Akinaga ,  Masami Okabe

    Inventor： Chikara Murakata ,  Fumihiko Kanai ,  Yutaka Saitoh ,  Yukimasa Shiotsu ,  Takako Shiraki ,  Tatsuya Tamaoki ,  Shiro Akinaga ,  Masami Okabe

    IPC: A61K31/40 ,  A61K31/404 ,  A61K31/407 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/495 ,  A61K31/496 ,  A61K31/535 ,  A61K31/5377 ,  C07D403/14 ,  C07D487/14 ,  C07D487/12

    CPC classification number: C07D403/14 ,  A61K31/40 ,  A61K31/404 ,  A61K31/407 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/495 ,  A61K31/496 ,  A61K31/535 ,  A61K31/5377 ,  C07D487/14

    Abstract: The present invention provides a method of treating thrombocytopenia, which comprises administering to a patient suffering from thrombocytopenia, an effective amount of an indolocarbazole derivative represented by formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group or a tetrahydropyranyl group; R.sup.2A and R.sup.3A, which may be the same or different, each represent a hydrogen atom, a substituted or unsubstituted lower alkyl group, a lower alkenyl group, a substituted or unsubstituted aralkyl group or a monosaccharide residue where a hydroxyl group at the anomer position is removed; R.sup.4A and R.sup.5A, which may be the same or different, each represent a hydrogen atom, a formyl group, a hydroxyl group or a halogen atom; W.sup.A1 and W.sup.A2 represent hydrogen atoms or are combined together to form an oxygen atom; and X.sup.A1 and X.sup.A2 represents two hydrogen atoms or are combined together to form a single bond, provided that when X.sup.A forms a single bond, then R.sup.1, R.sup.2A, R.sup.3A, R.sup.4A, R.sup.5A, and W.sup.A do not simultaneously represent a hydrogen atom, or a pharmaceutically acceptable salt.

    Abstract translation: 本发明提供一种治疗血小板减少症的方法，其包括向患有血小板减少症的患者施用有效量的由式（I）表示的吲哚并咔唑衍生物：其中R 1表示氢原子，取代或 未取代的低级烷基，取代或未取代的芳烷基或四氢吡喃基; R2A和R3A可以相同或不同，分别表示氢原子，取代或未取代的低级烷基，低级链烯基，取代或未取代的芳烷基或单末端残基，其中前体位置的羟基为 删除 R4A和R5A可以相同或不同，分别表示氢原子，甲酰基，羟基或卤素原子; WA1和WA2表示氢原子，或者组合在一起形成氧原子; 并且XA1和XA2表示两个氢原子，或者组合在一起形成单键，条件是当XA形成单键时，则R1，R2A，R3A，R4A，R5A和WA不同时表示氢原子，或 药学上可接受的盐。

    INDAZOLE DERIVATIVES
    12.
    发明申请
    INDAZOLE DERIVATIVES 失效
    吲哚衍生物

    公开(公告)号：US20090082348A1

    公开(公告)日：2009-03-26

    申请号：US12275614

    申请日：2008-11-21

    Applicant: Yoshihisa Ohta ,  Fumihiko Kanai ,  Shinji Nara ,  Yutaka Kanda ,  Hiroshi Umehara ,  Yukimasa Shiotsu ,  Tomoki Naoe ,  Hitoshi Kiyoi ,  Keiko Kawashima ,  Hiromi Ando ,  Motoki Miyama

    Inventor： Yoshihisa Ohta ,  Fumihiko Kanai ,  Shinji Nara ,  Yutaka Kanda ,  Hiroshi Umehara ,  Yukimasa Shiotsu ,  Tomoki Naoe ,  Hitoshi Kiyoi ,  Keiko Kawashima ,  Hiromi Ando ,  Motoki Miyama

    IPC: A61K31/5377 ,  A61K31/416 ,  A61K31/496 ,  A61K31/454 ,  A61K31/506 ,  A61K31/4439 ,  A61P35/00

    CPC classification number: C07D231/56

    Abstract: The present invention provides a compound represented by Formula (I): [wherein R1 represents CONR1aR1b (wherein R1a and R1b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R1a and R1b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, R2 represents a hydrogen atom, CONR2aR2b (wherein R2a and R2b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R2a and R2b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NR2cR2d (wherein R2c and R2d may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].

    Abstract translation: 本发明提供由式（I）表示的化合物：[其中R1表示CONR1aR1b（其中R1a和R1b可以相同或不同，各自表示氢原子，取代或未取代的低级烷基，取代或未取代的芳基，取代或未取代的 芳基或取代或未取代的杂环基，或者R1a和R1b与相邻的氮原子一起形成取代或未取代的杂环基）等，R2表示氢原子，CONR2aR2b（其中R2a和R2b可以是 各自表示氢原子，取代或未取代的低级烷基，取代或未取代的芳基，取代或未取代的芳基或取代或未取代的杂环基，或者R 2a和R 2b与相邻的氮原子一起形成取代基 或未取代的杂环基），NR2cR2d（其中R2c和R2d可以相同或不同 取代或未取代的芳酰基，取代或未取代的芳酰基，取代或未取代的低级烷基磺酰基或取代或未取代的低级芳基磺酰基）等。 。

    Indazole derivatives
    13.
    发明授权
    Indazole derivatives 失效
    吲唑衍生物

    公开(公告)号：US07470717B2

    公开(公告)日：2008-12-30

    申请号：US10548475

    申请日：2004-07-30

    Applicant: Yoshihisa Ohta ,  Fumihiko Kanai ,  Shinji Nara ,  Yutaka Kanda ,  Hiroshi Umehara ,  Yukimasa Shiotsu ,  Tomoki Naoe ,  Hitoshi Kiyoi ,  Keiko Kawashima ,  Hiromi Ando ,  Motoki Miyama

    Inventor： Yoshihisa Ohta ,  Fumihiko Kanai ,  Shinji Nara ,  Yutaka Kanda ,  Hiroshi Umehara ,  Yukimasa Shiotsu ,  Tomoki Naoe ,  Hitoshi Kiyoi ,  Keiko Kawashima ,  Hiromi Ando ,  Motoki Miyama

    IPC: A61K31/416 ,  C07D231/56

    CPC classification number: C07D231/56

    Abstract: The present invention provides a compound represented by Formula (I): [wherein R1 represents CONR1aR1b (wherein R1a and R1b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R1a and R1b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, R2 represents a hydrogen atom, CONR2aR2b (wherein R2a and R2b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R2a and R2b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NR2cR2d (wherein R2c and R2d may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].

    Abstract translation: 本发明提供由式（I）表示的化合物：[其中R1表示CONR1aR1b（其中R1a和R1b可以相同或不同，各自表示氢原子，取代或未取代的低级烷基，取代或未取代的芳基，取代或未取代的 芳烷基或取代或未取代的杂环基，或者R1a和R1b与相邻的氮原子一起形成取代或未取代的杂环基）等，R2表示氢原子，CONR2aR2b（其中R2a和R2b可以是 各自表示氢原子，取代或未取代的低级烷基，取代或未取代的芳基，取代或未取代的芳烷基或取代或未取代的杂环基，或R 2a和R 2b与相邻的氮原子一起形成取代基 或未取代的杂环基），NR2cR2d（其中R2c和R2d可以相同或不同 取代或未取代的杂芳酰基，取代或未取代的芳烷基，取代或未取代的低级烷基磺酰基或取代或未取代的低级芳基磺酰基）等，其中R 1代表氢原子，取代或未取代的低级烷基，取代或未取代的低级烷酰基，取代或未取代的芳酰基， 。

Patent Agency Ranking